Iain S Mcgregor

List of Publications by Year
in descending order

279	15,629	13099 68	26613 107
papers	citations	h-index	g-index

285	285	285	11584
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The effects of predator odors in mammalian prey species: A review of field and laboratory studies. Neuroscience and Biobehavioral Reviews, 2005, 29, 1123-1144.	6.1	685
2	Defensive behavior in rats towards predatory odors: a review. Neuroscience and Biobehavioral Reviews, 2001, 25, 597-609.	6.1	388
3	Adolescent Rats Find Repeated Î”9-THC Less Aversive Than Adult Rats but Display Greater Residual Cognitive Deficits and Changes in Hippocampal Protein Expression Following Exposure. Neuropsychopharmacology, 2008, 33, 1113-1126.	5.4	271
4	Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. Journal of Psychopharmacology, 2004, 18, 502-508.	4.0	238
5	Breaking the loop: Oxytocin as a potential treatment for drug addiction. Hormones and Behavior, 2012, 61, 331-339.	2.1	236
6	Not all â€˜predator odoursâ€™ are equal: cat odour but not 2,4,5 trimethylthiazoline (TMT; fox odour) elicits specific defensive behaviours in rats. Behavioural Brain Research, 2002, 129, 1-16.	2.2	219
7	Increased motivation for beer in rats following administration of a cannabinoid CB1 receptor agonist. European Journal of Pharmacology, 1999, 370, 233-240.	3.5	216
8	Chronic cannabinoid exposure produces lasting memory impairment and increased anxiety in adolescent but not adult rats. Journal of Psychopharmacology, 2004, 18, 502-508.	4.0	215
9	Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. ACS Chemical Neuroscience, 2016, 7, 1241-1254.	3.5	214
10	Repeated cannabinoid exposure during perinatal, adolescent or early adult ages produces similar longlasting deficits in object recognition and reduced social interaction in rats. Journal of Psychopharmacology, 2006, 20, 611-621.	4.0	213
11	Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal. JAMA Psychiatry, 2014, 71, 281.	11.0	209
12	A role for oxytocin and 5-HT1A receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (â€œecstasyâ€). Neuroscience, 2007, 146, 509-514.	2.3	207
13	Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chemical Neuroscience, 2015, 6, 1546-1559.	3.5	202
14	Modulation of anxiety-related behaviours following lesions of the prelimbic or infralimbic cortex in the rat. Brain Research, 1997, 772, 181-190.	2.2	201
15	Neural Correlates of Cat Odor-Induced Anxiety in Rats: Region-Specific Effects of the Benzodiazepine Midazolam. Journal of Neuroscience, 2004, 24, 4134-4144.	3.6	200
16	Trends in the utilisation of psychotropic medications in Australia from 2000 to 2011. Australian and New Zealand Journal of Psychiatry, 2013, 47, 74-87.	2.3	187
17	A behavioural comparison of acute and chronic Î”9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. International Journal of Neuropsychopharmacology, 2010, 13, 861-876.	2.1	167
18	Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chemical Neuroscience, 2015, 6, 1445-1458.	3.5	167

#	Article	IF	Citations
19	Cannabidiol potentiates Î”9-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology, 2011, 218, 443-457.	3.1	166
20	The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABA A receptors. Pharmacological Research, 2017, 119, 358-370.	7.1	164
21	Analysis of Cannabis Seizures in NSW, Australia: Cannabis Potency and Cannabinoid Profile. PLoS ONE, 2013, 8, e70052.	2.5	161
22	Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharmacology Biochemistry and Behavior, 1996, 53, 657-664.	2.9	159
23	From ultrasocial to antisocial: a role for oxytocin in the acute reinforcing effects and longâ€term adverse consequences of drug use?. British Journal of Pharmacology, 2008, 154, 358-368.	5.4	153
24	TMT-induced autonomic and behavioral changes and the neural basis of its processing. Neuroscience and Biobehavioral Reviews, 2005, 29, 1145-1156.	6.1	141
25	Oxytocin decreases methamphetamine self-administration, methamphetamine hyperactivity, and relapse to methamphetamine-seeking behaviour in rats. Neuropharmacology, 2010, 58, 38-43.	4.1	138
26	The cardiovascular and behavioral response to cat odor in rats: unconditioned and conditioned effects. Brain Research, 2001, 897, 228-237.	2.2	133
27	Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Psychopharmacology, 2019, 236, 2713-2724.	3.1	130
28	Cannabinoid receptor activation inhibits GABAergic neurotransmission in rostral ventromedial medulla neurons in vitro. British Journal of Pharmacology, 1999, 127, 935-940.	5.4	124
29	Adolescent Oxytocin Exposure Causes Persistent Reductions in Anxiety and Alcohol Consumption and Enhances Sociability in Rats. PLoS ONE, 2011, 6, e27237.	2.5	123
30	Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine (â€œEcstasyâ€). European Journal of Pharmacology, 2001, 433, 91-99.	3.5	120
31	Systemically administered oxytocin decreases methamphetamine activation of the subthalamic nucleus and accumbens core and stimulates oxytocinergic neurons in the hypothalamus. Addiction Biology, 2010, 15, 448-463.	2.6	119
32	The First CNS-Active Carborane: A Novel P2X₇ Receptor Antagonist with Antidepressant Activity. ACS Chemical Neuroscience, 2014, 5, 335-339.	3.5	118
33	Acute Prosocial Effects of Oxytocin and Vasopressin When Given Alone or in Combination with 3,4-Methylenedioxymethamphetamine in Rats: Involvement of the V1A Receptor. Neuropsychopharmacology, 2013, 38, 2249-2259.	5.4	112
34	Effect of Cannabidiol and Î”⁹-Tetrahydrocannabinol on Driving Performance. JAMA - Journal of the American Medical Association, 2020, 324, 2177.	7.4	106
35	A doubleâ€blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome. American Journal of Medical Genetics, Part A, 2014, 164, 2232-2239.	1.2	103
36	Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia, 2019, 60, 2224-2234.	5.1	103

#	Article	IF	Citations
37	Habituation of the hiding response to cat odor in rats (Rattus norvegicus).. Journal of Comparative Psychology (Washington, D C: 1983), 1999, 113, 376-387.	0.5	100
38	Increased Anxiety 3 Months after Brief Exposure to MDMA (â€˜Ecstasyâ€™) in Rats: Association with Altered 5-HT Transporter and Receptor Density. Neuropsychopharmacology, 2003, 28, 1472-1484.	5.4	99
39	Cat odor, but not trimethylthiazoline (fox odor), activates accessory olfactory and defense-related brain regions in rats. Neuroscience, 2008, 151, 937-947.	2.3	99
40	(Â±)-3,4-Methylenedioxymethamphetamine (MDMA, â€˜Ecstasyâ€™) increases social interaction in rats. European Journal of Pharmacology, 2000, 408, 41-49.	3.5	98
41	Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies. Sleep Medicine Reviews, 2020, 53, 101339.	8.5	96
42	Resilience and reduced c-Fos expression in P2X7 receptor knockout mice exposed to repeated forced swim test. Neuroscience, 2011, 189, 170-177.	2.3	95
43	Low-Dose Midazolam Attenuates Predatory Odor Avoidance in Rats. Pharmacology Biochemistry and Behavior, 1999, 62, 197-201.	2.9	94
44	Consumption of high carbohydrate, high fat, and normal chow is equally suppressed by a cannabinoid receptor antagonist in non-deprived rats. Neuroscience Letters, 2004, 354, 217-220.	2.1	94
45	Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: a cross-sectional survey. BMJ Open, 2018, 8, e022101.	1.9	94
46	Metabolic effects of neuropeptide Y injections into the paraventricular nucleus of the hypothalamus. Brain Research, 1990, 516, 8-14.	2.2	90
47	A brief history of oxytocin and its role in modulating psychostimulant effects. Journal of Psychopharmacology, 2013, 27, 231-247.	4.0	90
48	A Metaâ€Analysis on the Impact of Alcohol Dependence on Shortâ€Term Restingâ€State Heart Rate Variability: Implications for Cardiovascular Risk. Alcoholism: Clinical and Experimental Research, 2013, 37, E23-9.	2.4	89
49	Increased anxiety in rats after 3,4-methylenedioxymethamphetamine: association with serotonin depletion. European Journal of Pharmacology, 2002, 446, 89-96.	3.5	88
50	Oxytocin directly administered into the nucleus accumbens core or subthalamic nucleus attenuates methamphetamine-induced conditioned place preference. Behavioural Brain Research, 2012, 228, 185-193.	2.2	88
51	MDMA (Ecstasy) neurotoxicity: assessing and communicating the risks. Lancet, The, 2000, 355, 1818-1821.	13.7	86
52	Longitudinal trends in the dispensing of psychotropic medications in Australia from 2009â€“2012: Focus on children, adolescents and prescriber specialty. Australian and New Zealand Journal of Psychiatry, 2014, 48, 917-931.	2.3	84
53	Absence of Entourage: Terpenoids Commonly Found inCannabis sativaDo Not Modulate the Functional Activity of Î”⁹-THC at Human CB₁and CB₂Receptors. Cannabis and Cannabinoid Research, 2019, 4, 165-176.	2.9	84
54	Possible neural substrates of beer-craving in rats. Neuroscience Letters, 1998, 252, 99-102.	2.1	83

#	Article	IF	Citations
55	High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: Neural consequences and comparison with methamphetamine. Journal of Psychopharmacology, 2013, 27, 823-836.	4.0	82
56	Distinct Neurobehavioural Effects of Cannabidiol in Transmembrane Domain Neuregulin 1 Mutant Mice. PLoS ONE, 2012, 7, e34129.	2.5	80
57	The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse. ACS Chemical Neuroscience, 2013, 4, 1081-1092.	3.5	80
58	Increased anxiety and "depressive" symptoms months after MDMA ("ecstasy") in rats: drug-induced hyperthermia does not predict long-term outcomes. Psychopharmacology, 2003, 168, 465-474.	3.1	79
59	Chronic Fluoxetine Treatment Partly Attenuates the Long-Term Anxiety and Depressive Symptoms Induced by MDMA (â€˜Ecstasyâ€™) in Rats. Neuropsychopharmacology, 2004, 29, 694-704.	5.4	79
60	Determining the magnitude and duration of acute Î”9-tetrahydrocannabinol (Î”9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review. Neuroscience and Biobehavioral Reviews, 2021, 126, 175-193.	6.1	79
61	Oxytocin inhibits ethanol consumption and ethanolâ€•induced dopamine release in the nucleus accumbens. Addiction Biology, 2017, 22, 702-711.	2.6	78
62	A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine. Brain Research, 2004, 1026, 244-253.	2.2	77
63	Mephedrone (4â€•methylmethcathinone, â€˜meowâ€™): acute behavioural effects and distribution of Fos expression in adolescent rats. Addiction Biology, 2012, 17, 409-422.	2.6	77
64	Pharmacokinetics of Phytocannabinoid Acids and Anticonvulsant Effect of Cannabidiolic Acid in a Mouse Model of Dravet Syndrome. Journal of Natural Products, 2019, 82, 3047-3055.	3.0	77
65	Cannabinoid modulation of rat pup ultrasonic vocalizations. European Journal of Pharmacology, 1996, 313, 43-49.	3.5	75
66	The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain. Brain Research, 2001, 921, 240-255.	2.2	75
67	Paraventricular hypothalamic CB1 cannabinoid receptors are involved in the feeding stimulatory effects of Î”9-tetrahydrocannabinol. Neuropharmacology, 2005, 49, 1101-1109.	4.1	73
68	MDMA (â€œecstasyâ€•, methamphetamine and their combination: long-term changes in social interaction and neurochemistry in the rat. Psychopharmacology, 2004, 173, 318-325.	3.1	72
69	Heterozygous neuregulin 1 mice display greater baseline and Î”9-tetrahydrocannabinol-induced c-Fos expression. Neuroscience, 2007, 149, 861-870.	2.3	72
70	Reintoxication: the release of fatâ€•stored Î”⁹â€•tetrahydrocannabinol (THC) into blood is enhanced by food deprivation or ACTH exposure. British Journal of Pharmacology, 2009, 158, 1330-1337.	5.4	72
71	Medical cannabis use in the Australian community following introduction of legal access: the 2018â€“2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). Harm Reduction Journal, 2020, 17, 37.	3.2	72
72	Inflammation and Breakdown of the Bloodâ€“Retinal Barrier During â€œPhysiological Agingâ€•in the Rat Retina: A Model for CNS Aging. Microcirculation, 2007, 14, 63-76.	1.8	70

#	Article	IF	Citations
73	Body temperature and cardiac changes induced by peripherally administered oxytocin, vasopressin and the nonâ€peptide oxytocin receptor agonist <scp>WAY</scp> 267,464: a biotelemetry study in rats. British Journal of Pharmacology, 2014, 171, 2868-2887.	5.4	70
74	Oxytocin prevents ethanol actions at Î´ subunit-containing GABA _A receptors and attenuates ethanol-induced motor impairment in rats. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 3104-3109.	7.1	70
75	Transmembrane domain Nrg1 mutant mice show altered susceptibility to the neurobehavioural actions of repeated THC exposure in adolescence. International Journal of Neuropsychopharmacology, 2013, 16, 163-175.	2.1	69
76	Oxytocin in the nucleus accumbens core reduces reinstatement of methamphetamineâ€seeking behaviour in rats. Addiction Biology, 2016, 21, 316-325.	2.6	69
77	Molecular and Behavioral Pharmacological Characterization of Abused Synthetic Cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-Fluoro-CUMYL-PICA. Journal of Pharmacology and Experimental Therapeutics, 2018, 365, 437-446.	2.5	69
78	Heat increases 3,4-methylenedioxymethamphetamine self-administration and social effects in rats. European Journal of Pharmacology, 2003, 482, 339-341.	3.5	68
79	Heart rate variability predicts alcohol craving in alcohol dependent outpatients: Further evidence for HRV as a psychophysiological marker of self-regulation. Drug and Alcohol Dependence, 2013, 132, 395-398.	3.2	68
80	Cannabichromene is a cannabinoid CB₂ receptor agonist. British Journal of Pharmacology, 2019, 176, 4537-4547.	5.4	68
81	Nabiximols for the Treatment of Cannabis Dependence. JAMA Internal Medicine, 2019, 179, 1242.	5.1	68
82	Protein expression profile in the striatum of acute methamphetamine-treated rats. Brain Research, 2006, 1097, 19-25.	2.2	66
83	The schizophrenia susceptibility gene neuregulin 1 modulates tolerance to the effects of cannabinoids. International Journal of Neuropsychopharmacology, 2011, 14, 631-643.	2.1	66
84	Medicinal cannabis in Australia, 2016: the Cannabis as Medicine Survey (CAMSâ€16). Medical Journal of Australia, 2018, 209, 211-216.	1.7	66
85	The Cannabinoid Receptor Agonist THC Attenuates Weight Loss in a Rodent Model of Activity-Based Anorexia. Neuropsychopharmacology, 2011, 36, 1349-1358.	5.4	63
86	The Nonpeptide Oxytocin Receptor Agonist WAY 267,464: Receptorâ€Binding Profile, Prosocial Effects and Distribution of câ€Fos Expression in Adolescent Rats. Journal of Neuroendocrinology, 2012, 24, 1012-1029.	2.6	63
87	Neural activation during cat odor-induced conditioned fear and â€˜trial 2â€™ fear in rats. Neuroscience and Biobehavioral Reviews, 2005, 29, 1265-1277.	6.1	61
88	Serotonin (1A) receptor involvement in acute 3,4-methylenedioxymethamphetamine (MDMA) facilitation of social interaction in the rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2005, 29, 648-657.	4.8	61
89	Repeated weekly exposure to MDMA, methamphetamine or their combination: Long-term behavioural and neurochemical effects in rats. Drug and Alcohol Dependence, 2007, 86, 183-190.	3.2	60
90	A comparison of Î”9-THC and anandamide induced c-fos expression in the rat forebrain. Brain Research, 1998, 802, 19-26.	2.2	58

#	Article	IF	Citations
91	Evidence for an interaction between CB1 cannabinoid and oxytocin receptors in food and water intake. Neuropharmacology, 2004, 47, 593-603.	4.1	58
92	Defensive responses of Wistar and Sprague-Dawley rats to cat odour and TMT. Behavioural Brain Research, 2006, 172, 351-354.	2.2	58
93	Pre-exposure to the cannabinoid receptor agonist CP 55,940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats. European Journal of Pharmacology, 2003, 465, 105-114.	3.5	57
94	Mephedrone in Adolescent Rats: Residual Memory Impairment and Acute but Not Lasting 5-HT Depletion. PLoS ONE, 2012, 7, e45473.	2.5	56
95	Cannabidiol treatment reduces the motivation to self-administer methamphetamine and methamphetamine-primed relapse in rats. Journal of Psychopharmacology, 2018, 32, 1369-1378.	4.0	56
96	An Australian nationwide survey on medicinal cannabis use for epilepsy: History of antiepileptic drug treatment predicts medicinal cannabis use. Epilepsy and Behavior, 2017, 70, 334-340.	1.7	55
97	Dark Classics in Chemical Neuroscience: Î”⁹-Tetrahydrocannabinol. ACS Chemical Neuroscience, 2019, 10, 2160-2175.	3.5	55
98	Effects of pre-exposure and co-administration of the cannabinoid receptor agonist CP 55,940 on behavioral sensitization to cocaine. European Journal of Pharmacology, 1998, 354, 9-16.	3.5	54
99	The distribution of Î³-hydroxybutyrate-induced Fos expression in rat brain: Comparison with baclofen. Neuroscience, 2009, 158, 441-455.	2.3	54
100	Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues. ACS Chemical Neuroscience, 2017, 8, 2159-2167.	3.5	53
101	Effects of the cannabinoid receptor agonist CP 55,940 and the cannabinoid receptor antagonist SR 141716 on intracranial self-stimulation in Lewis rats. Life Sciences, 2001, 70, 97-108.	4.3	52
102	Combined low dose treatment with opioid and cannabinoid receptor antagonists synergistically reduces the motivation to consume alcohol in rats. Psychopharmacology, 2004, 173, 210-216.	3.1	52
103	Cannabinoids prevent the acute hyperthermia and partially protect against the 5-HT depleting effects of MDMA (â€œEcstasyâ€) in rats. Neuropharmacology, 2004, 46, 954-965.	4.1	52
104	Deletion of TDO2, IDO-1 and IDO-2 differentially affects mouse behavior and cognitive function. Behavioural Brain Research, 2016, 312, 102-117.	2.2	52
105	Oxytocin and vasopressin modulate the social response to threat: a preclinical study. International Journal of Neuropsychopharmacology, 2014, 17, 1621-1633.	2.1	50
106	Intranasal oxytocin in the treatment of anorexia nervosa: Randomized controlled trial during re-feeding. Psychoneuroendocrinology, 2018, 87, 83-92.	2.7	50
107	Access to cannabidiol without a prescription: A cross-country comparison and analysis. International Journal of Drug Policy, 2020, 85, 102935.	3.3	50
108	The dopamine receptor antagonist SCH 23390 attenuates feeding induced by Î”9-tetrahydrocannabinol. Brain Research, 2004, 1020, 188-195.	2.2	48

#	Article	IF	Citations
109	Regional c-Fos and FosB/Î”FosB expression associated with chronic methamphetamine self-administration and methamphetamine-seeking behavior in rats. Neuroscience, 2012, 206, 100-114.	2.3	48
110	Î”9-THC REINSTATES BEER- AND SUCROSE-SEEKING BEHAVIOUR IN ABSTINENT RATS: COMPARISON WITH MIDAZOLAM, FOOD DEPRIVATION AND PREDATOR ODOUR. Alcohol and Alcoholism, 2005, 40, 35-45.	1.6	47
111	Topiramate Moderately Reduces the Motivation to Consume Alcohol and Has a Marked Antidepressant Effect in Rats. Alcoholism: Clinical and Experimental Research, 2007, 31, 1900-1907.	2.4	47
112	Predatory threat induces huddling in adolescent rats and residual changes in early adulthood suggestive of increased resilience. Behavioural Brain Research, 2011, 225, 405-414.	2.2	47
113	Changes in cigarette and alcohol use during cannabis abstinence. Drug and Alcohol Dependence, 2014, 138, 54-60.	3.2	46
114	Cyclooxygenaseâ€2 in the Pathogenesis of Murine Cerebral Malaria. Journal of Infectious Diseases, 2004, 189, 751-758.	4.0	45
115	Fear, risk assessment, and playfulness in the juvenile rat.. Behavioral Neuroscience, 2006, 120, 49-59.	1.2	45
116	Proteomic Analysis Demonstrates Adolescent Vulnerability to Lasting Hippocampal Changes Following Chronic Alcohol Consumption. Alcoholism: Clinical and Experimental Research, 2009, 33, 86-94.	2.4	45
117	Defensive Aggregation (Huddling) in Rattus Norvegicus toward Predator Odor: Individual Differences, Social Buffering Effects and Neural Correlates. PLoS ONE, 2013, 8, e68483.	2.5	45
118	Synthesis and pharmacology of new psychoactive substance 5Fâ€ŒUMYLâ€Ƥ7AICA, a scaffoldâ€•hopping analog of synthetic cannabinoid receptor agonists 5Fâ€ŒUMYLâ€ƤICA and 5Fâ€ŒUMYLâ€ƤINACA. Drug Testing and Analysis, 2019, 11, 279-291.	2.6	45
119	The pro-inflammatory cytokine interferon-gamma is an important driver of neuropathology and behavioural sequelae in experimental pneumococcal meningitis. Brain, Behavior, and Immunity, 2014, 40, 252-268.	4.1	44
120	Perinatal Exposure to Î”9-Tetrahydrocannabinol Alters Heroin-Induced Place Conditioning and Fos-Immunoreactivity. Neuropsychopharmacology, 2006, 31, 58-69.	5.4	43
121	Adolescent preâ€treatment with oxytocin protects against adult methamphetamineâ€seeking behavior in female rats. Addiction Biology, 2016, 21, 304-315.	2.6	43
122	MDMA (â€˜Ecstasyâ€™) and methamphetamine combined: Order of administration influences hyperthermic and long-term adverse effects in female rats. Neuropharmacology, 2005, 49, 195-207.	4.1	42
123	The consequences of beer consumption in rats: acute anxiolytic and ataxic effects and withdrawal-induced anxiety. Psychopharmacology, 2003, 166, 51-60.	3.1	41
124	MDMA, methamphetamine and their combination: possible lessons for party drug users from recent preclinical research. Drug and Alcohol Review, 2007, 26, 9-15.	2.1	41
125	MDMA-induced c-Fos expression in oxytocin-containing neurons is blocked by pretreatment with the 5-HT-1A receptor antagonist WAY 100635. Brain Research Bulletin, 2011, 86, 65-73.	3.0	41
126	Composition and Use of Cannabis Extracts for Childhood Epilepsy in the Australian Community. Scientific Reports, 2018, 8, 10154.	3.3	41

#	Article	IF	Citations
127	The cannabinoid receptor antagonist SRï¿½141716 attenuates overfeeding induced by systemic or intracranial morphine. Psychopharmacology, 2003, 168, 314-323.	3.1	40
128	Protein expression profile in the striatum of rats with methamphetamine-induced behavioral sensitization. Proteomics, 2007, 7, 1131-1139.	2.2	40
129	Prescribing medicinal cannabis. Australian Prescriber, 2020, 43, 152-159.	1.0	40
130	Dopaminergic modulation of rat pup ultrasonic vocalizations. European Journal of Pharmacology, 1999, 382, 53-67.	3.5	39
131	On the anxiogenic and anxiolytic nature of long-term cerebral 5-HT depletion following MDMA. Psychopharmacology, 2002, 162, 448-450.	3.1	39
132	Intermittent access to beer promotes binge-like drinking in adolescent but not adult Wistar rats. Alcohol, 2009, 43, 305-314.	1.7	39
133	Rapid quantitation of fluoxetine and norfluoxetine in serum by micro-disc solid-phase extraction with high-performance liquid chromatographyâ€“ultraviolet absorbance detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 804, 319-326.	2.3	38
134	ABC transporters P-gp and Bcrp do not limit the brain uptake of the novel antipsychotic and anticonvulsant drug cannabidiol in mice. PeerJ, 2016, 4, e2081.	2.0	38
135	Terpenoids Commonly Found in Cannabis sativa Do Not Modulate the Actions of Phytocannabinoids or Endocannabinoids on TRPA1 and TRPV1 Channels. Cannabis and Cannabinoid Research, 2020, 5, 305-317.	2.9	38
136	The role of the vasopressin V1A receptor in oxytocin modulation of methamphetamine primed reinstatement. Neuropharmacology, 2018, 133, 1-11.	4.1	37
137	Involvement of hypothalamic peptides in the anorectic action of the CB₁ receptor antagonist rimonabant (SR 141716). European Journal of Neuroscience, 2009, 29, 2207-2216.	2.6	36
138	Moderate alcohol intake is related to increased heart rate variability in young adults: Implications for health and wellâ€being. Psychophysiology, 2013, 50, 1202-1208.	2.4	36
139	Oxytocin and MDMA (â€˜Ecstasyâ€™) enhance social reward in rats. Psychopharmacology, 2015, 232, 2631-2641.	3.1	35
140	In vitro and in vivo pharmacokinetics and metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA. Forensic Toxicology, 2017, 35, 333-347.	2.4	35
141	Rats on the grog: Novel pharmacotherapies for alcohol craving. Addictive Behaviors, 2004, 29, 1341-1357.	3.0	34
142	Rats discriminate individual cats by their odor: Possible involvement of the accessory olfactory system. Neuroscience and Biobehavioral Reviews, 2008, 32, 1209-1217.	6.1	34
143	Aggregation in quads but not pairs of rats exposed to cat odor or bright light. Behavioural Processes, 2012, 90, 331-336.	1.1	34
144	Exercise increases plasma THC concentrations in regular cannabis users. Drug and Alcohol Dependence, 2013, 133, 763-767.	3.2	34

#	Article	IF	Citations
145	Active coping toward predatory stress is associated with lower corticosterone and progesterone plasma levels and decreased methylation in the medial amygdala vasopressin system. Hormones and Behavior, 2014, 66, 561-566.	2.1	34
146	Cannabidiol and Sports Performance: a Narrative Review of Relevant Evidence and Recommendations for Future Research. Sports Medicine - Open, 2020, 6, 27.	3.1	34
147	Cocaine and heroin (â€˜speedballâ€™) self-administration: the involvement of nucleus accumbens dopamine and Î¼-opiate, but not Î´-opiate receptors. Psychopharmacology, 2005, 180, 21-32.	3.1	33
148	Synthetic Cannabinoid Hydroxypentyl Metabolites Retain Efficacy at Human Cannabinoid Receptors. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 414-422.	2.5	33
149	Using Strawberry Tree WorkbenchMac and Workbench PC software for data acquisition and control in the animal learning laboratory. Behavior Research Methods, 1996, 28, 38-48.	1.3	32
150	Beer Consumption in Rats. Alcohol, 1999, 17, 47-56.	1.7	32
151	Detection of Î”⁹ THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two pointâ€ofâ€collection testing devices. Drug Testing and Analysis, 2019, 11, 1486-1497.	2.6	32
152	CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist. Frontiers in Pharmacology, 2019, 10, 595.	3.5	32
153	Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy. British Journal of Pharmacology, 2021, 178, 4826-4841.	5.4	32
154	Protein expression profile in the amygdala of rats with methamphetamine-induced behavioral sensitization. Neuroscience Letters, 2008, 435, 113-119.	2.1	31
155	Differential behavioural and neurochemical outcomes from chronic paroxetine treatment in adolescent and adult rats: a model of adverse antidepressant effects in human adolescents?. International Journal of Neuropsychopharmacology, 2011, 14, 491-504.	2.1	31
156	Novel molecular changes induced by Nrg1 hypomorphism and Nrg1-cannabinoid interaction in adolescence: a hippocampal proteomic study in mice. Frontiers in Cellular Neuroscience, 2013, 7, 15.	3.7	31
157	Adolescent exposure to oxytocin, but not the selective oxytocin receptor agonist TGOT, increases social behavior and plasma oxytocin in adulthood. Hormones and Behavior, 2014, 65, 488-496.	2.1	31
158	Interactions between cannabidiol and Î”⁹â€tetrahydrocannabinol in modulating seizure susceptibility and survival in a mouse model of Dravet syndrome. British Journal of Pharmacology, 2020, 177, 4261-4274.	5.4	30
159	Serotonergic modulation of 3,4-methylenedioxymethamphetamine (MDMA)-elicited reduction of response rate but not rewarding threshold in accumbal self-stimulation. Brain Research, 1997, 744, 351-357.	2.2	29
160	Disruptive effects of the prototypical cannabinoid Î”9-tetrahydrocannabinol and the fatty acid amide inhibitor URB-597 on go/no-go auditory discrimination performance and olfactory reversal learning in rats. Behavioural Pharmacology, 2011, 22, 191-202.	1.7	29
161	Lithium carbonate in the management of cannabis withdrawal: a randomized placebo-controlled trial in an inpatient setting. Psychopharmacology, 2014, 231, 4623-4636.	3.1	29
162	Parameters That Affect Fear Responses in Rodents and How to Use Them for Management. Frontiers in Ecology and Evolution, 2019, 7, .	2.2	29

#	Article	IF	Citations
163	Metabolic effects obtained from excitatory amino acid stimulation of the sulcal prefrontal cortex. Brain Research, 1990, 529, 1-6.	2.2	28
164	Residual social, memory and oxytocin-related changes in rats following repeated exposure to Î³-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination. Psychopharmacology, 2010, 212, 663-674.	3.1	28
165	Preliminary evidence for lowered basal cortisol in a naturalistic sample of methamphetamine polydrug users.. Experimental and Clinical Psychopharmacology, 2012, 20, 497-503.	1.8	28
166	Toxic by design? Formation of thermal degradants and cyanide from carboxamide-type synthetic cannabinoids CUMYL-PICA, 5F-CUMYL-PICA, AMB-FUBINACA, MDMB-FUBINACA, NNEI, and MN-18 during exposure to high temperatures. Forensic Toxicology, 2019, 37, 17-26.	2.4	28
167	Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome. ACS Chemical Neuroscience, 2021, 12, 330-339.	3.5	28
168	Long-lasting FosB/Î”FosB immunoreactivity in the rat brain after repeated cat odor exposure. Neuroscience Letters, 2009, 462, 157-161.	2.1	27
169	The failings of per se limits to detect cannabis-induced driving impairment: Results from a simulated driving study. Traffic Injury Prevention, 2021, 22, 102-107.	1.4	27
170	Structureâ€“activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. Forensic Toxicology, 2015, 33, 355-366.	2.4	26
171	Cannabinoids increase conditioned ultrasonic vocalisations and cat odour avoidance in rats: Strain differences in drug-induced anxiety. Life Sciences, 2010, 87, 572-578.	4.3	25
172	Long-term daily access to alcohol alters dopamine-related synthesis and signaling proteins in the rat striatum. Neurochemistry International, 2012, 61, 1280-1288.	3.8	25
173	Intravenous methamphetamine self-administration in rats: Effects of intravenous or intraperitoneal MDMA co-administration. Pharmacology Biochemistry and Behavior, 2006, 85, 454-463.	2.9	24
174	Neuroadaptations in the Striatal Proteome of the Rat Following Prolonged Excessive Sucrose Intake. Neurochemical Research, 2014, 39, 815-824.	3.3	24
175	Driving-Related Behaviours, Attitudes and Perceptions among Australian Medical Cannabis Users: Results from the CAMS 18-19 Survey. Accident Analysis and Prevention, 2020, 148, 105784.	5.7	24
176	Cannabidiol (CBD) and Î”⁹-tetrahydrocannabinol (THC) for chronic insomnia disorder (â€˜CANSLEEPâ€™ trial): protocol for a randomised, placebo-controlled, double-blinded, proof-of-concept trial. BMJ Open, 2020, 10, e034421.	1.9	24
177	Citalopram and Cannabidiol. Journal of Clinical Psychopharmacology, 2021, 41, 525-533.	1.4	24
178	A long hangover from party drugs: Residual proteomic changes in the hippocampus of rats 8 weeks after Î³-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination. Neurochemistry International, 2010, 56, 871-877.	3.8	23
179	A Nose for Death: Integrating Trophic and Informational Networks for Conservation and Management. Frontiers in Ecology and Evolution, 2016, 4, .	2.2	23
180	Effects of cannabidiol on simulated driving and cognitive performance: A dose-ranging randomised controlled trial. Journal of Psychopharmacology, 2022, 36, 1338-1349.	4.0	23

#	Article	IF	Citations
181	Constrasting effects of dopaminergic blockade on MDMA and d-amphetamine conditioned taste aversions. Pharmacology Biochemistry and Behavior, 1994, 47, 369-374.	2.9	22
182	Co-administration of THC and MDMA (â€˜Ecstasyâ€™) Synergistically Disrupts Memory in Rats. Neuropsychopharmacology, 2005, 30, 1475-1482.	5.4	21
183	Chronic repetitive transcranial magnetic stimulation is antidepressant but not anxiolytic in rat models of anxiety and depression. Psychiatry Research, 2005, 137, 113-121.	3.3	21
184	Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. Journal of Psychopharmacology, 2017, 31, 757-769.	4.0	21
185	Endocannabinoid dysregulation in cognitive and stress-related brain regions in the Nrg1 mouse model of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 72, 9-15.	4.8	21
186	Gain-of-function GABRB3 variants identified in vigabatrin-hypersensitive epileptic encephalopathies. Brain Communications, 2020, 2, fcaa162.	3.3	21
187	Contrasting effects of dopamine antagonists and frequency reduction on Fos expression induced by lateral hypothalamic stimulation. Behavioural Brain Research, 2002, 132, 187-201.	2.2	20
188	Sedative and hypothermic effects of Î³-hydroxybutyrate (GHB) in rats alone and in combination with other drugs: Assessment using biotelemetry. Drug and Alcohol Dependence, 2009, 103, 137-147.	3.2	20
189	Metabolomics of Neurotransmitters and Related Metabolites in Post-Mortem Tissue from the Dorsal and Ventral Striatum of Alcoholic Human Brain. Neurochemical Research, 2016, 41, 385-397.	3.3	20
190	Functional genomics of epilepsy-associated mutations in the GABAA receptor subunits reveal that one mutation impairs function and two are catastrophic. Journal of Biological Chemistry, 2019, 294, 6157-6171.	3.4	20
191	Reduced sensitivity to MDMA-induced facilitation of social behaviour in MDMA pre-exposed rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008, 32, 1013-1021.	4.8	19
192	Antipsychotic Induced Alteration of Growth and Proteome of Rat Neural Stem Cells. Neurochemical Research, 2012, 37, 1649-1659.	3.3	19
193	Hippocampal protein expression is differentially affected by chronic paroxetine treatment in adolescent and adult rats: a possible mechanism of â€œparadoxicalâ€•antidepressant responses in young persons. Frontiers in Pharmacology, 2013, 4, 86.	3.5	19
194	WAY 267,464, a non-peptide oxytocin receptor agonist, impairs social recognition memory in rats through a vasopressin 1A receptor antagonist action. Psychopharmacology, 2015, 232, 2659-2667.	3.1	19
195	Regional c-Fos expression induced by peripheral oxytocin administration is prevented by the vasopressin 1A receptor antagonist SR49059. Brain Research Bulletin, 2016, 127, 208-218.	3.0	19
196	Urinary cannabinoid levels during nabiximols (SativexÂ®)-medicated inpatient cannabis withdrawal. Forensic Toxicology, 2017, 35, 33-44.	2.4	19
197	Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial. Drug and Alcohol Dependence, 2020, 215, 108220.	3.2	19
198	Medical cannabis and driving. Australian Journal of General Practice, 2021, 50, 357-362.	0.8	19

#	Article	IF	Citations
199	Medicinal Cannabis Prescribing in Australia: An Analysis of Trends Over the First Five Years. Frontiers in Pharmacology, 2022, 13, .	3.5	19
200	Differential protein expression in the corpus callosum (body) of human alcoholic brain. Journal of Neurochemistry, 2009, 110, 486-495.	3.9	18
201	â€˜When an old rat smells a catâ€™: A decline in defense-related, but not accessory olfactory, Fos expression in aged rats. Neurobiology of Aging, 2011, 32, 737-749.	3.1	18
202	Inhaled vasopressin increases sociability and reduces body temperature and heart rate in rats. Psychoneuroendocrinology, 2014, 46, 46-51.	2.7	18
203	Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials. Addiction Biology, 2022, 27, e13125.	2.6	18
204	Preexposure to MDMA (â€œEcstasyâ€) delays acquisition but facilitates MDMA-induced reinstatement of amphetamine self-administration behavior in rats. Pharmacology Biochemistry and Behavior, 2004, 79, 331-342.	2.9	17
205	Driving on ice: impaired driving skills in current methamphetamine users. Psychopharmacology, 2013, 225, 161-172.	3.1	17
206	Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: a study protocol. BMC Psychiatry, 2018, 18, 140.	2.6	17
207	The chemistry and pharmacology of putative synthetic cannabinoid receptor agonist (SCRA) new psychoactive substances (NPS) 5Fâ€PYâ€PICA, 5Fâ€PYâ€PINACA, and their analogs. Drug Testing and Analysis, 2019, 11, 976-989.	2.6	17
208	Stressor-like effects of FG-7142 on medial prefrontal cortex self-stimulation. Brain Research, 1990, 516, 170-174.	2.2	16
209	High ambient temperature increases intravenous methamphetamine self-administration on fixed and progressive ratio schedules in rats. Journal of Psychopharmacology, 2008, 22, 100-110.	4.0	16
210	Effects of typical (haloperidol) and atypical (risperidone) antipsychotic agents on protein expression in rat neural stem cells. Neurochemistry International, 2009, 55, 558-565.	3.8	16
211	Beer promotes high levels of alcohol intake in adolescent and adult alcohol-preferring rats. Alcohol, 2011, 45, 485-498.	1.7	16
212	The Effects of Lithium Carbonate Supplemented with Nitrazepam on Sleep Disturbance during Cannabis Abstinence. Journal of Clinical Sleep Medicine, 2015, 11, 1153-1162.	2.6	16
213	Oral cannabinoid-rich THC/CBD cannabis extract for secondary prevention of chemotherapy-induced nausea and vomiting: a study protocol for a pilot and definitive randomised double-blind placebo-controlled trial (CannabisCINV). BMJ Open, 2018, 8, e020745.	1.9	16
214	Medicinal cannabis and driving: the intersection of health and road safety policy. International Journal of Drug Policy, 2021, 97, 103307.	3.3	16
215	Prefrontal cortex Î±2 adrenoceptors and energy balance. Brain Research Bulletin, 1991, 26, 683-691.	3.0	15
216	Comparison of conditioned taste aversions produced by MDMA and d-amphetamine. Pharmacology Biochemistry and Behavior, 1993, 46, 153-156.	2.9	15

#	Article	IF	Citations
217	Stress-induced changes in respiratory quotient, energy expenditure and locomotor activity in rats: effects of midazolam. Psychopharmacology, 1994, 116, 475-482.	3.1	15
218	Rubbings deposited by cats elicit defensive behavior in rats. Physiology and Behavior, 2012, 107, 711-718.	2.1	15
219	Medicinal cannabis in the treatment of chronic pain. Australian Journal of General Practice, 2021, 50, 724-732.	0.8	15
220	Are blood and oral fluid Î”9-tetrahydrocannabinol (THC) and metabolite concentrations related to impairment? A meta-regression analysis. Neuroscience and Biobehavioral Reviews, 2022, 134, 104433.	6.1	15
221	Low and high doses of midazolam differentially affect hypoalgesia in rats conditioned to a heat stressor. Psychopharmacology, 1993, 111, 62-68.	3.1	14
222	Antibody-induced neutrophil depletion prior to the onset of pneumococcal meningitis influences long-term neurological complications in mice. Brain, Behavior, and Immunity, 2016, 56, 68-83.	4.1	14
223	A validated method for the simultaneous quantification of cannabidiol, Î”⁹â€tetrahydrocannabinol, and their metabolites in human plasma and application to plasma samples from an oral cannabidiol openâ€label trial. Drug Testing and Analysis, 2021, 13, 614-627.	2.6	14
224	Cannabinoids, Insomnia, and Other Sleep Disorders. Chest, 2022, 162, 452-465.	0.8	14
225	Metabolic changes associated with ingestion of different macronutrients and different meal sizes in rats. Physiology and Behavior, 1995, 57, 277-286.	2.1	13
226	Comparative proteomics in the corpus callosal sub-regions of postmortem human brain. Neurochemistry International, 2009, 55, 483-490.	3.8	13
227	MDMA (â€˜Ecstasyâ€™), oxytocin and vasopressin modulate social preference in rats: A role for handling and oxytocin receptors. Pharmacology Biochemistry and Behavior, 2016, 150-151, 115-123.	2.9	13
228	The effect of cannabidiol on simulated car driving performance: A randomised, doubleâ€blind, placeboâ€controlled, crossover, doseâ€ranging clinical trial protocol. Human Psychopharmacology, 2020, 35, e2749.	1.5	13
229	Evaluation of the Possible Anticonvulsant Effect of Î”⁹-Tetrahydrocannabinolic Acid in Murine Seizure Models. Cannabis and Cannabinoid Research, 2022, 7, 46-57.	2.9	13
230	Asymmetric Suppression of Components in Binary Aldehyde Mixtures: Behavioral Studies in the Laboratory Rat. Chemical Senses, 2006, 32, 191-199.	2.0	12
231	Antidepressants and adolescent brain development. Future Neurology, 2011, 6, 783-808.	0.5	12
232	Altered behaviour and cognitive function following combined deletion of Toll-like receptors 2 and 4 in mice. Behavioural Brain Research, 2016, 303, 1-8.	2.2	12
233	The chemistry and pharmacology of synthetic cannabinoid SDBâ€006 and its regioisomeric fluorinated and methoxylated analogs. Drug Testing and Analysis, 2018, 10, 1099-1109.	2.6	12
234	The effect of COVID19 pandemic restrictions on an urban rodent population. Scientific Reports, 2021, 11, 12957.	3.3	12

#	Article	IF	Citations
235	An automated two-choice test of olfactory working memory in the rat: Effect of scopolamine. Cognitive, Affective and Behavioral Neuroscience, 2000, 28, 21-31.	1.3	12
236	Footshock stress facilitates self-stimulation of the medial prefrontal cortex but not the lateral hypothalamus in the rat. Brain Research, 1989, 490, 397-403.	2.2	11
237	Kinetic and metabolic profiles of synthetic cannabinoids NNEI and MNâ€18. Drug Testing and Analysis, 2018, 10, 137-147.	2.6	11
238	In vitro and in vivo pharmacological evaluation of the synthetic cannabinoid receptor agonist EG-018. Pharmacology Biochemistry and Behavior, 2020, 193, 172918.	2.9	11
239	Orally administered cannabidiol does not produce falseâ€positive tests for Î”⁹â€tetrahydrocannabinol on the Securetec DrugWipeÂ® 5S or DrÃger DrugTestÂ® 5000. Drug Testing and Analysis, 2022, 14, 137-143.	2.6	11
240	Structureâ€“activity relationships of valine, tert-leucine, and phenylalanine amino acid-derived synthetic cannabinoid receptor agonists related to ADB-BUTINACA, APP-BUTINACA, and ADB-P7AICA. RSC Medicinal Chemistry, 2022, 13, 156-174.	3.9	11
241	Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition. Drug and Alcohol Review, 2022, 41, 1095-1108.	2.1	11
242	Benzodiazepines impair the acquisition and reversal of olfactory go/no-go discriminations in rats.. Behavioral Neuroscience, 2007, 121, 527-534.	1.2	10
243	The kynurenine pathway contributes to long-term neuropsychological changes in experimental pneumococcal meningitis. Behavioural Brain Research, 2014, 270, 179-195.	2.2	10
244	Effects of Cannabidiol on Exercise Physiology and Bioenergetics: A Randomised Controlled Pilot Trial. Sports Medicine - Open, 2022, 8, 27.	3.1	10
245	Double deficiency of toll-like receptors 2 and 4 alters long-term neurological sequelae in mice cured of pneumococcal meningitis. Scientific Reports, 2019, 9, 16189.	3.3	9
246	Antipredator responses toward cat fur in wild brown rats tested in a semi-natural environment. Behavioral Ecology, 0, , .	2.2	9
247	Changes in Respiratory Quotient Elicited in Rats by a Conditioned Stimulus Predicting Food. Physiology and Behavior, 1998, 63, 227-232.	2.1	8
248	Pyrazolo[1,4]diazepines as non-peptidic probes of the oxytocin and vasopressin receptors. Tetrahedron Letters, 2014, 55, 4568-4571.	1.4	8
249	Medicinal Cannabis for Inflammatory Bowel Disease: A Survey of Perspectives, Experiences, and Current Use in Australian Patients. Crohn's & Colitis 360, 2020, 2, .	1.1	8
250	Regional Fos-expression induced by Î³-hydroxybutyrate (GHB): Comparison with Î³-butyrolactone (GBL) and effects of co-administration of the GABAB antagonist SCH 50911 and putative GHB antagonist NCS-382. Neuroscience, 2014, 277, 700-715.	2.3	7
251	Fasting and exercise increase plasma cannabinoid levels in THC pre-treated rats: an examination of behavioural consequences. Psychopharmacology, 2014, 231, 3987-3996.	3.1	7
252	NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity?. ACS Chemical Neuroscience, 2021, 12, 4020-4036.	3.5	7

#	Article	IF	Citations
253	Determination of contaminants in artisanal cannabis products used for childhood epilepsy in the Australian community: A sub-analysis of the â€˜PELICANâ€™ study. Epilepsy and Behavior, 2022, 127, 108496.	1.7	7
254	A nutraceutical product, extracted from Cannabis sativa, modulates voltage-gated sodium channel function. Journal of Cannabis Research, 2022, 4, .	3.2	7
255	Contrasting regional Fos expression in adolescent and young adult rats following acute administration of the antidepressant paroxetine. Brain Research Bulletin, 2016, 121, 246-254.	3.0	6
256	Cannabichromene and Î”⁹-Tetrahydrocannabinolic Acid Identified as Lactate Dehydrogenase-A Inhibitors by in Silico and in Vitro Screening. Journal of Natural Products, 2021, 84, 1469-1477.	3.0	6
257	Olivetolic acid, a cannabinoid precursor in Cannabis sativa, but not CBGA methyl ester exhibits a modest anticonvulsant effect in a mouse model of Dravet syndrome. Journal of Cannabis Research, 2022, 4, 2.	3.2	6
258	Defining Steric Requirements at CB₁ and CB₂ Cannabinoid Receptors Using Synthetic Cannabinoid Receptor Agonists 5F-AB-PINACA, 5F-ADB-PINACA, PX-1, PX-2, NNL-1, and Their Analogues. ACS Chemical Neuroscience, 2022, 13, 1281-1295.	3.5	6
259	Randomised controlled trial (RCT) of daily aerobic exercise for inpatient cannabis withdrawal: A study protocol. Mental Health and Physical Activity, 2017, 13, 57-67.	1.8	5
260	Oxytocin as an adolescent treatment for methamphetamine addiction after early life stress in male and female rats. Neuropsychopharmacology, 2022, 47, 1561-1573.	5.4	5
261	A Potential Drug-Gene-Drug Interaction Between Cannabidiol, CYP2D6*4, and Fluoxetine. Journal of Clinical Psychopharmacology, 2022, 42, 422-424.	1.4	5
262	Controllability of prestimulation of the medial prefrontal cortex determines the facilitation of self-stimulation and kindled seizures. Physiology and Behavior, 1989, 46, 239-245.	2.1	4
263	Defensive behavior. Neuroscience and Biobehavioral Reviews, 2005, 29, 1121-1122.	6.1	4
264	Behavioral and cognitive data in mice with different tryptophan-metabolizing enzymes knocked out. Data in Brief, 2016, 9, 275-287.	1.0	4
265	Putative Synthetic Cannabinoids MEPIRAPIM, 5F-BEPIRAPIM (NNL-2), and Their Analogues Are T-Type Calcium Channel (Ca_V3) Inhibitors. ACS Chemical Neuroscience, 2022, 13, 1395-1409.	3.5	4
266	Give me a hi-5! An additional version of the h-index. Australian and New Zealand Journal of Psychiatry, 2013, 47, 1119-1123.	2.3	3
267	Attitudes and Knowledge of Australian Gastroenterologists Around the Use of Medicinal Cannabis for Inflammatory Bowel Disease. Crohn's & Colitis 360, 2020, 2, .	1.1	3
268	The anticonvulsant zonisamide positively modulates recombinant and native glycine receptors at clinically relevant concentrations. Neuropharmacology, 2021, 182, 108371.	4.1	3
269	The effect of daily aerobic cycling exercise on sleep quality during inpatient cannabis withdrawal: A randomised controlled trial. Journal of Sleep Research, 2021, 30, e13211.	3.2	3
270	International conference on memory (ICOM-4), University of New South Wales, Sydney, Australia, 16â€”21 July 2006 Ecstasy/MDMA and Memory Symposium. Journal of Psychopharmacology, 2007, 21, 895-897.	4.0	2

#	Article	IF	Citations
271	P2X7 in Bipolar and Depressive Disorders. , 2014, , 635-661.		2
272	Oxytocin and addiction. , 0, , 270-287.		2
273	Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses. Psychopharmacology, 2022, 239, 1593-1603.	3.1	2
274	Cortisol response and psychological distress predict susceptibility to false memories for a trauma film. Memory, 2016, 24, 1278-1286.	1.7	1
275	Driving Impairment Following Vaporization of Cannabisâ€"Reply. JAMA - Journal of the American Medical Association, 2021, 325, 1226.	7.4	1
276	Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial. Drug and Alcohol Dependence, 2022, 234, 109388.	3.2	1
277	Response to: â€˜Cannabis use before safety sensitive work: What delay is prudent?â€™. Neuroscience and Biobehavioral Reviews, 2022, 137, 104684.	6.1	1
278	Cannabis use and non-cancer chronic pain. Lancet Public Health, The, 2018, 3, e467.	10.0	0
279	The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients. Journal of Cannabis Research, 2021, 3, 33.	3.2	0